Immunex Cororation, 51 University Street, Seattle, Washington 98101, USA.
J Immunol. 2011 Nov 1;187(9):4392-402.
Herpesvirus Saimiri gene 13 (HVS13) exhibits 57% identity with the predicted sequence of a T cell-derived molecule termed CTLA8. Recombinant HVS13 and CTLA8 stimulate transcriptional factor NF-kappaB activity and Interleukin-6 (IL-6) secretion in fibroblasts, and costimulate T cell proliferation. An HVS13.Fc fusion protein was used to isolate a cDNA encoding a novel receptor that also binds CTLA8. This receptor is unrelated to previously identified cytokine receptor families. A recombinant soluble receptor inhibited T cell proliferation and IL-2 production induced by PHA, concanavalin A (conA), and anti-TCR MAb. These results define CTLA8 and HVS13 as novel cytokines that bind to a novel cytokine receptor. We propose to call these molecules IL-17, vIL-17, and IL-17R, respectively.
猴疱疹病毒 13 基因（HVS13）与一种被称为 CTLA8 的 T 细胞衍生分子的预测序列具有 57%的同源性。重组 HVS13 和 CTLA8 可刺激成纤维细胞中转录因子 NF-κB 的活性和白细胞介素-6（IL-6）的分泌，并协同刺激 T 细胞增殖。HVS13.Fc 融合蛋白用于分离编码一种新型受体的 cDNA，该受体也与 CTLA8 结合。该受体与先前鉴定的细胞因子受体家族无关。一种重组可溶性受体抑制 PHA、刀豆蛋白 A（conA）和抗 TCR MAb 诱导的 T 细胞增殖和 IL-2 产生。这些结果定义 CTLA8 和 HVS13 为结合新型细胞因子受体的新型细胞因子。我们建议分别将这些分子称为 IL-17、vIL-17 和 IL-17R。
